Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Haloperidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20254453 | 1.00 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL8264 | 1.00 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL317367 | 0.99 | DRD2 (0.98) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL15545886 | 0.99 | DRD2 (0.98) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL28699132 | 0.98 | DRD2 (0.96) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL8741248 | 0.97 | DRD2 (0.94) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| SCHEMBL11752117 | 0.97 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL20644145 | 0.96 | DRD2 (0.92) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL9507217 | 0.96 | DRD2 (0.92) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| SCHEMBL9054984 | 0.94 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118043049-A | Sotosib and EGFR antibodies for the treatment of cancers comprising KRAS G12C mutations | 安进公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2017178682-A1 | COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ALCOHOL USE DISORDERS | SERVICIO ANDALUZ DE SALUD (ES) | 2017-10-19 | — | — | WO | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2012163990-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS TREATED WITH NEUROLEPTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| EP-1758600-A4 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MAN SCIENCES LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | disclosed |
| EP-1758600-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | Mood Management Sciences, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-1056469-A4 | NOVEL PEPTIDE COPOLYMER COMPOSITIONS | SUPRATEK PHARMA INC (CA) | 2003-05-07 | — | — | EP | disclosed |
| EP-1056469-A1 | NOVEL PEPTIDE COPOLYMER COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2000-12-06 | — | — | EP | disclosed |
| EP-1014977-A1 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP LIMITED (GB) | 2000-07-05 | — | — | EP | disclosed |
| EP-1014977-A4 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP LTD (GB) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999043343-A1 | NOVEL PEPTIDE COPOLYMER COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-09-02 | — | — | WO | disclosed |
| US-5861423-A | SIDE EFFECT REDUCTION; ADMINISTERING TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER*S AND PARKINSON*S DISEASE; ATTENTION DEFICIT DISORDER, SCHIZOPHRENIA | TARGACEPT, INC., A CORPORATION OF DELAWARE | 1999-01-19 | — | — | US | disclosed |
| EP-0839026-A1 | POLYETHER BLOCK COPOLYMER MICELLAR COMPOSITIONS FOR TARGETING BIOLOGICAL AGENTS | SUPRATEK PHARMA, INC. (CA) | 1998-05-06 | — | — | EP | disclosed |
| WO-1998007426-A1 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP, LTD. (GB) | 1998-02-26 | — | — | WO | disclosed |
| WO-1996040056-A1 | POLYETHER BLOCK COPOLYMER MICELLAR COMPOSITIONS FOR TARGETING BIOLOGICAL AGENTS | SUPRATEK PHARMA INC. (CA) | 1996-12-19 | — | — | WO | disclosed |